In a presentation posted by BioNTech on Monday the company said, it can “potentially” deliver about 2 billion doses of its Covid-19 vaccine by the end of 2021.
Previously, Pfizer CEO Albert Bourla said the companies would manufacture 1.3 billion doses in 2021, but noted, “We are working very diligently to increase this number.”
BioNTech pointed to the updated label allowing for six doses as one of the factors to help increase supply capacity.
Originally, product labels said each vial had five doses available after dilution, but after it was discovered that there was enough leftover solution to potentially squeeze out extra doses, the FDA updated its guidance to say, “it is acceptable to use every full dose obtainable (the sixth, or possibly even a seventh) from each vial.”
BioNTech also said the 2 billion doses goal, “is based on continuous process improvements and expansion at our current facilities, and contingent upon adding more suppliers as well as contract manufacturers.”
The company also said 32.9 million doses have shipped globally as of Jan. 10, 2021.